Literature DB >> 21451260

Protein phosphatase 1 regulators in DNA damage signaling.

Thomas Küntziger1, Helga B Landsverk, Philippe Collas, Randi G Syljuåsen.   

Abstract

In response to DNA damaging agents and endogenous DNA lesions, human cells activate signaling cascades and repair mechanisms to help maintain genomic integrity. Phosphorylation plays a major role in DNA damage signaling, and the role of Ser/Thr kinases, including ATM, ATR, CHK1, CHK2 and DNA-PK, is particularly well documented. While these kinases have taken the center stage in DNA damage signaling until now, a role for Ser/Thr phosphatases is emerging, including Protein Phosphatase 1 (PP1). PP1 substrate specificity is regulated by its binding to a large number of different targeting subunits, and several of these have recently been identified as regulators of DNA damage responses. Here we review recent progress regarding the involvement of PP1 and its binding partners in DNA damage signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21451260     DOI: 10.4161/cc.10.9.15442

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

Review 1.  What goes on must come off: phosphatases gate-crash the DNA damage response.

Authors:  Dong-Hyun Lee; Dipanjan Chowdhury
Journal:  Trends Biochem Sci       Date:  2011-09-18       Impact factor: 13.807

2.  Wip1 contributes to cell homeostasis maintained by the steady-state level of Wtp53.

Authors:  Hwan Ki Park; Jayabal Panneerselvam; Fred Duafalia Dudimah; Guangzhi Dong; Sinto Sebastian; Jun Zhang; Peiwen Fei
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

3.  Dephosphorylation activates the interferon-stimulated Schlafen family member 11 in the DNA damage response.

Authors:  Dane Malone; Rea M Lardelli; Manqing Li; Michael David
Journal:  J Biol Chem       Date:  2019-08-08       Impact factor: 5.157

4.  Chk1 modulates the interaction between myosin phosphatase targeting protein 1 (MYPT1) and protein phosphatase 1cβ (PP1cβ).

Authors:  Xiaomei Hu; Zhe Li; Yuehe Ding; Qizhi Geng; Zhikai Xiahou; Huanwei Ru; Meng-Qiu Dong; Xingzhi Xu; Jing Li
Journal:  Cell Cycle       Date:  2018-03-19       Impact factor: 4.534

5.  Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors.

Authors:  I Ferrer; E M Verdugo-Sivianes; M A Castilla; R Melendez; J J Marin; S Muñoz-Galvan; J L Lopez-Guerra; B Vieites; M J Ortiz-Gordillo; J M De León; J M Praena-Fernandez; M Perez; J Palacios; A Carnero
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

6.  R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott-Aldrich syndrome.

Authors:  Koustav Sarkar; Seong-Su Han; Kuo-Kuang Wen; Hans D Ochs; Loïc Dupré; Michael M Seidman; Yatin M Vyas
Journal:  J Allergy Clin Immunol       Date:  2017-12-15       Impact factor: 10.793

Review 7.  Recent progress in studies of arterivirus- and coronavirus-host interactions.

Authors:  Yanxin Zhong; Yong Wah Tan; Ding Xiang Liu
Journal:  Viruses       Date:  2012-06-19       Impact factor: 5.048

8.  Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1α) docking protein.

Authors:  Tony Ferrar; Delphine Chamousset; Veerle De Wever; Mhairi Nimick; Jens Andersen; Laura Trinkle-Mulcahy; Greg B G Moorhead
Journal:  Biol Open       Date:  2011-11-24       Impact factor: 2.422

9.  Response to DNA damage: why do we need to focus on protein phosphatases?

Authors:  Midori Shimada; Makoto Nakanishi
Journal:  Front Oncol       Date:  2013-01-31       Impact factor: 6.244

Review 10.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Richard A Franklin; Giuseppe Montalto; Melchiorre Cervello; Massimo Libra; Saverio Candido; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Ferdinando Nicoletti; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Francesca Chiarini; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.